Background: Type 2 diabetes (T2D) is a metabolic condition which increases the risk of cardiovascular disease (CVD) and chronic kidney disease (CKD). Despite these risks, many people with diabetes do not meet treatment goals and thus remain at increased risk of mortality and morbidity associated with diabetes. Two classes of drugs known as sodium-glucose-cotransporter- 2-inhibitors (SGLT2 inhibitor) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) have transformed the way obesity, CVD, and CKD is managed in patients with diabetes. Despite their benefits, many people with diabetes are not prescribed these medications as part of an antihyperglycemic regimen.
Methods: This study examined the prescribing patterns for patients with T2D and target comorbidities, including established or high-risk CVD, CKD, obesity, and high hypoglycemia risk in an ambulatory care clinic. Adults were included if they had uncontrolled T2D. The primary objective of this study was to describe the prescribing prevalence of SGLT2 inhibitors and GLP-1 RAs for patients with uncontrolled T2D and target comorbidities. We also compared the demographic characteristics of patients by prescribing patterns.
Results: A total of 16 individuals were included in the study. Overall, 62.5% of all patients were not on an SGLT2 inhibitor or GLP-1 RA despite demonstrated potential benefit(s). Approximately 33% of obese patients, 50% of individuals with CKD or at high risk for CVD, and 40% of individuals having high hypoglycemia risk were on an SGLT2 inhibitor or a GLP-1 RA.
Conclusion: Prescribing of SGLT2 inhibitors and GLP-1 RAs was low in patients with high ASCVD risk, high hypoglycemia risk, obesity, and CKD.
Citation: Salem D, Vincent Ekenga V, Ekenga C. 2022. Prescribing Patterns of SGLT2 Inhibitors and GLP-1 RAs in Patients with Type 2 Diabetes and Comorbid Conditions of Cardiovascular Disease, Chronic Kidney Disease, and Obesity J Obes Chronic Dis 6(1): 9-14.